DUBLIN--(BUSINESS WIRE)--The "Frontier Pharma: Renal Diseases - High Degree of Innovation and Diversity with Products Targeting Immune and Hormone Signaling Dominating the Pipeline for Chronic Kidney Disease" drug pipelines has been added to Research and Markets' offering.
Majority of marketed products for renal diseases are small molecules, which account for more than 95% of all products. There are only a small number of other molecule types such as monoclonal antibodies (mAb) and proteins available in the market.
The pipeline is highly diverse in terms of molecule type. Unlike the marketed products, the pipeline contains a wide range of other molecule types, including proteins, mAbs, synthetic peptides, cell therapies and vaccines. While small molecules account for majority of the marketed products, they only account for about 60% of the pipeline. This is partly due to the relatively large proportion of biologics.
Drug development for renal diseases has significantly lagged behind other therapy areas, and very few novel therapies have been approved in the last decade. The marketed pharmacotherapeutic treatments for renal diseases typically focus on controlling the risk factors and complications of renal failure. Treatments include anti-hypertensive agents, hormones, antibiotics, and systemic immunosuppressants.
Key Topics Covered:
1. List of Tables & Figures
2 Executive Summary
2.1 Unmet Need and Limited Treatment Options Despite Rising Prevalence
2.2 Increasing Number of Pipeline Biologics
2.3 Significant Degree of First-in-Class Innovation
2.4 Low Deal Volume but Large Proportion of High-Value Deals
3 The Case for Innovation
3.1 Growing Opportunities for Biologic Products
3.2 Diversification of Molecular Targets
3.3 Innovative First-in-Class Product Developments Remain Attractive
3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation
3.5 Sustained Innovation
3.6 Research Report Guidance
4 Clinical and Commercial Landscape
4.1 Disease Overview
4.2 Symptoms
4.3 Diagnosis
4.4 Etiology and Pathophysiology
4.5 Epidemiology
4.6 Co-morbidities and Complications
4.7 Treatment Options
4.8 Overview of Marketed Products
4.9 Current Unmet Needs
5 Assessment of Pipeline Product Innovation
5.1 Pipeline by Stage of Development, Molecule Type and Molecular Target
5.2 First-in-Class Programs Targeting Novel Molecular Targets
6 Renal Diseases Signaling Network, Disease Causation and Innovation Alignment
6.1 Complexity of Signaling Networks
6.2 Signaling Pathways and First-in-Class Molecular Target Integration
6.3 First-in-Class Matrix Assessment
7 First-in-Class Target and Pipeline Program Evaluation
7.1 Pipeline Programs Targeting Complement Factor D
7.2 Pipeline Programs Targeting Midkine
7.3 Pipeline Programs Targeting Galectin-3
7.4 Pipeline Programs Targeting Connective Tissue Growth Factor
7.5 Pipeline Programs Targeting CX3C Chemokine Receptor 1
7.6 Pipeline Programs Targeting C-C Chemokine Receptor Type 2
7.7 Pipeline Programs Targeting Lysyl Oxidase and Lysyl Oxidase Homolog 2
7.8 Pipeline Programs Targeting Tumor Necrosis Factor Receptor Superfamily Member 5
7.9 Conclusion
8 Strategic Consolidations
8.1 Industry-Wide First-in-Class Deals
8.2 Licensing Deals
8.3 Co-development Deals
8.4 List of First-in-Class Pipeline Products with and Without Prior Deal Involvement
9 Appendix
For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/7m8bcc/frontier_pharma
